Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | HTR2C | P28335 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | HTR1D | P28221 | 3/20 | 1.00 |
| ▸ | HTR1B | P28222 | 3/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161850 | 0.90 | MRGPRX1 (1.00) | MRGPRX1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL1162246 | 0.74 | MRGPRX1 (1.00) | MRGPRX1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL5563711 | 0.65 | SMN1; SMN2 (0.72) | — | |
| SCHEMBL6030180 | 0.63 | ALDH1A1 (0.66) | — | |
| SCHEMBL19337640 | 0.62 | NPC1 (0.72) | — | |
| SCHEMBL18658593 | 0.62 | CHRM3 (0.56) | MRGPRX1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL3637331 | 0.61 | HDAC1 (1.00) | — | |
| SCHEMBL13500915 | 0.61 | CYBB (0.80) | — | |
| SCHEMBL9124077 | 0.61 | PKM (0.54) | HTR2AHTR2CDRD2DRD3 | |
| SCHEMBL4578619 | 0.61 | KCNH2 (0.73) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462435-A2 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN | California Institute of Technology (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20110150769-A1 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN | THE JOHN HOPKINS UNIVERSITY | 2011-06-23 | — | — | US | disclosed |
| WO-2011017564-A2 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150769-A1 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN | MRGPRX1, MRGPRX2, OPRL1 | MRGPRX1 1/4885HTR2A 471/4885HTR2C 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.